NASDAQ:ASNDAscendis Pharma A/S Stock Price, Forecast & News

Ascendis Pharma A/S's stock was trading at $118.53 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ASND shares have increased by 23.8% and is now trading at $146.79. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ascendis Pharma A/S.

Ascendis Pharma A/S is scheduled to release its next quarterly earnings announcement on Wednesday, August 26th 2020. View our earnings forecast for Ascendis Pharma A/S.

Ascendis Pharma A/S (NASDAQ:ASND) released its quarterly earnings results on Tuesday, May, 19th. The biotechnology company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.43) by $0.11. The biotechnology company had revenue of $2.45 million for the quarter, compared to the consensus estimate of $2.66 million. Ascendis Pharma A/S had a negative net margin of 2,231.94% and a negative return on equity of 36.56%. View Ascendis Pharma A/S's earnings history.

11 brokerages have issued twelve-month target prices for Ascendis Pharma A/S's stock. Their forecasts range from $145.00 to $208.00. On average, they anticipate Ascendis Pharma A/S's share price to reach $172.09 in the next year. This suggests a possible upside of 17.2% from the stock's current price. View analysts' price targets for Ascendis Pharma A/S.

Media headlines about ASND stock have trended very negative on Friday, according to InfoTrie. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ascendis Pharma A/S earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutAscendis Pharma A/S.

Ascendis Pharma A/S saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 1,930,000 shares, a decline of 5.9% from the April 30th total of 2,050,000 shares. Based on an average trading volume of 228,000 shares, the days-to-cover ratio is currently 8.5 days. Approximately 4.3% of the company's shares are sold short. View Ascendis Pharma A/S's Current Options Chain.

Some companies that are related to Ascendis Pharma A/S include Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Genmab A/S (GMAB), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), UCB (UCBJF), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Beigene (BGNE), Sarepta Therapeutics (SRPT) and Catalent (CTLT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Neurocrine Biosciences (NBIX), Alexion Pharmaceuticals (ALXN), Exelixis (EXEL), NVIDIA (NVDA), GW Pharmaceuticals PLC- (GWPH), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (BMRN), Crispr Therapeutics (CRSP) and Enterprise Products Partners (EPD).

(ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Ascendis Pharma A/S's stock is owned by many different retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (10.24%), Orbimed Advisors LLC (6.85%), Vivo Capital LLC (4.17%), Janus Henderson Group PLC (3.89%), Wellington Management Group LLP (3.48%) and Franklin Resources Inc. (1.46%).

ASND stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., Camber Capital Management LP, Franklin Resources Inc., State Street Corp, Orbimed Advisors LLC, Ghost Tree Capital LLC, and Wellington Management Group LLP.

ASND stock was acquired by a variety of institutional investors in the last quarter, including Vivo Capital LLC, RA Capital Management L.P., Janus Henderson Group PLC, Spyglass Capital Management LLC, Asymmetry Capital Management L.P., JPMorgan Chase & Co., New York State Common Retirement Fund, and ARS Investment Partners LLC.

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ASND stock can currently be purchased for approximately $146.79.

Ascendis Pharma A/S has a market capitalization of $7.04 billion and generates $14.98 million in revenue each year. The biotechnology company earns $-244,180,000.00 in net income (profit) each year or ($5.25) on an earnings per share basis. Ascendis Pharma A/S employs 216 workers across the globe.

The official website for Ascendis Pharma A/S is www.ascendispharma.com.

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]